reading 503B threads from 2024 and half of it aged badly
reading 503B threads from 2024 and half of it aged badly. I have gone back and forth on this for months. The five questions worth asking before you commit to any compounded arrangement. Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the…
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
Reminder that nothing here is medical advice and this board cannot tell you which arrangement to choose.
do not assume the concentration matches the branded product
What did the intake actually ask you?
a telehealth intake that asks nothing has told you what it is
salt forms are the recurring argument and the answer is boring
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
Did they name the facility?